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Heart failure is a leading cause of morbidity and mortality in the developed world. Cardiac 
injury with a significant loss of cardiomyocytes usually leads to a common final pathway of 
cardiac pathological remodelling that includes fibrosis, and the development and progression 
of heart failure. The treatment of chronic heart failure generally relies on strategies designed 
to target and limit cardiac ischemia, additional tissue damage, pathological cardiac remodel-
ling, or hemodynamic impairment and cardiac dyssynchrony. Moreover, understanding of the 
pathways that chauffeur pathological remodelling as opposed tomyocardial repair and re-
generation in the failing heart still remains challenging. The identification of stem cells has, 
however, opened new prospects for the development of cell-based regenerative medicine 
[1]. Indeed, the heart may contain a pool of resident or circulation-derived stem cells, but, 
following injury, these endogenous cells are not sufficiently regenerative to fully repair-
damaged myocardium [2]. To overcome this insufficiency, treatments have been proposed 
with exogenous stem cells or their progeny, which may reduce pathological processes in the 
damaged heart and improve cardiac tissue regeneration in mice and humans. Despite con-
certed efforts to treat damaged myocardium through cell transplantation, it remains a matter 
of debate whether the delivery of stem cells or stem cell progeny contributes principally to 
new cardiac tissue formation, to the activation of endogenous repair mechanisms, or to the 
modulation of inflammatory processes [3]. More importantly, stem cell-based therapies have 
resulted in improved cardiac function, and the development of this line of research repre-
sents a new frontier in modern cardiovascular research. In this special issue of Stem Cells 
International, we have assembled a series of original manuscripts and review articles dealing 
with this research frontier. The articles describe a variety of novel strategies to obtain cells 
for cardiac repair or regeneration and discuss current efforts, available tools, and new meth-
ods for stem cell-based therapies. Pluripotent stem cells represent one potential source for 
stem cell-based therapy in the failing heart [4]; however, this kind of therapy has some seri-
ous limitations, ranging from ethical issues in humans to the degree of heterogeneity found in 
cultures of “purified” embryonic stem cell-derived cardiomyocytes (ESC-CMs). Following in-
jection into heart, previous studies demonstrated that ESC-CMs form grafts that may mediate 
long-term recovery of global and regional myocardial contractile function following infarction. 
In this issue, K. R. Boheler et al. [5] specifically addressed the question of developmental 
state and showed that immature hypoxia-resistant ESC-CMs can be isolated in mass in vitro. 
The authors suggested that the use of immature proliferating CMs that do not seem to form 
tumors in vivo may serve as a source of innately hypoxia-resistant CMs useful in the treat-
ment of ischemic cardiac disorders. Such an approach might become a viable strategy for 
treating human cardiac disease states and injuries in the future; however, several obstacles 
still need to be resolved, including potential immunological responses, safety, and durable 
improvement of cardiac function in large animal models.  In a separate paper, S. Schmit-
teckert et al. [6] propose the transcription factor Lbx1 as new marker of differentiating ESC-
CMs. Lbx1 plays a role in the migration of muscle progenitor cells in limb buds and deter-
mines neuronal differentiation processes [7, 8]. Since Lbx1 was largely expressed in differen-
tiating ESC-CMs, Lbx1 might represent a novel tool for the identification of proper cell source 
to induce the reparative processes in the injured heart. Moreover, this finding may provide a 
model system of Lbx1 target genes and signaling pathways involved in early heart failure 
caused by Lbx1 inactivation. An entirely new vision of stem cell-based therapy was pre-
sented by S. Liebau et al. [9]. In this paper, the authors focused on calcium-activated potas-
sium channels (SKCas) as important inducers of stem cell differentiation. SKCas are in-
volved in cardiac pacemaker-cell development from ESCs and morphological shaping of 
neural stem cells [10, 11]. SKCas are also important modulators of the cytoskeleton rear-
rangement [12]. Previously, these authors showed that increased SKCas channel activity 
resulted in a strong and fast differentiation of pluripotent cells followed by a cellfate determi-
nation into the cardiac lineage, mainly with a phenotype of cardiac pacemaker-like cells de-
rived from ESC and iPS cells [13]. Here, this group reported the successful generation and 
characterization of a murine ESC line overexpressing the subtype 4 of SKCas channels in a 
doxycycline-dependent manner. Overexpression of SKCas4 was increased in cardiac and 
pacemaker-like cells suggesting SKCas4 as a unique tool to characterize the differentiation 
of pluripotent cells into cardiac phenotypes. SKCas channelmediated stem cell differentiation 
might also be applicable to the human system. Although substantial efforts have been made 
to develop therapeutic strategies with stem cells to regenerate injured heart [3], there is in-
creasing evidence that stem cells modulate inflammatory processes in a paracrine fashion 
more so than through direct cardiac tissue regeneration [14]. Recent findings have also sug-
gested that the poor effectiveness of stem cell-based therapies in heart diseases is a result 
of nonphysiological microenvironment in affected cardiac tissue [14, 15]. In particular, in-
flamed myocardium seems to inhibit the cardio-regenerative capacity of transplanted stem 
cells, while promoting profibrotic processes. A growing body of evidences suggests that the 
specific signaling milieu of the affected heart is a key determinant of the fate and function of 
stem cells in the myocardium [16]. Coupling modulation of the myocardial microenvironment 
with patient-specific stem cells must, therefore, be considered before successful stem cell-
based therapies of heart disorders will be achieved. Accordingly, our special issue offers a 
comprehensive comparison of different sources of stem cells for heart regeneration in basic 
science and in clinical trials. Moreover, there is a discussion of the potential mechanisms 
involved in reparative processes [17, 18]. Finally, A. Kleger et al. [19] provided a comprehen-
sive review on the differential and developmental impact of lysophospholipids on cardiovas-
cular development, which represents a novel approach in the field and may have relevance 
for the niche environment. Taken together, the compilation of articles in this special issue of 
Stem Cells International, discusses the current state of stem cell-based therapies. The au-
thors address both experimental and clinical aspects of stem cell research aimed at improv-
ing the reparative processes in the failing heart. The three research articles specifically pro-
vide novel information designed either to select for specific types of stem cells or to induce 
the differentiation of pluripotent cells into the phenotype of cardiac lineages. The reviews also 
offer a broad-based view of current efforts designed to understand the response of stem cells 
in a “niche” environment or in response to specific molecules. We hope that this issue will be 
helpful and interesting for basic researchers as well as for clinicians interested in or perform-
ing experiments designed to address relevant cardiac issues in regenerative medicine.  
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